Fujifilm Diosynth Biotechnologies to establish new viral vector manufacturing facility in Boston
The $40 million investment marks the company's third viral vector manufacturing site
Fujifilm is investing 4 billion yen ($40 million) in its contract development and manufacturing organization (CDMO), Fujifilm Diosynth Biotechnologies, to build a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area.
The new facility, which represents the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies, is scheduled to begin process development operations in autumn 2021.
The company's decision to expand manufacturing capacity comes as a direct response to the growing viral vector sector, which is focused on using genes to treat or prevent disease.
The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.
The CDMO chose the greater-Boston area to establish its new site for its high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies.
In 2014, Fujifilm Corporation established viral vector manufacturing offering at the Fujifilm Diosynth Biotechnologies’ site in Texas, US. As the market for viral vectors has continued to expand, Fujifilm has invested a further 13 billion yen (approx. $120 million) in the Texas site to build a new process development facility and to expand existing manufacturing facilities.
More recently, in October last year, Fujifilm Diosynth Biotechnologies announced an investment to provide process and analytical development, and cGMP manufacturing of viral vectors in the UK.
“Together these three sites will enable us to respond to our customers’ needs to support their viral vector manufacturing process from early clinical stage through to commercialization, to ensure these life-saving treatments are available to patients in need,” said Martin Meeson, Chief Executive Officer, Fujifilm Diosynth Biotechnologies.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance